What Zofenil Treats: Main Uses and Benefits

Zofenil, containing the active substance zofenopril calcium, belongs to the class of medicines known as Angiotensin-Converting Enzyme (ACE) inhibitors. Its primary therapeutic applications are focused on managing specific cardiovascular conditions.

Zofenil is used across conditions presenting with acute episodes and is indicated for the treatment of essential hypertension (high blood pressure) and acute myocardial infarction (heart attack). This makes it relevant in clinical settings that involve acute or unstable symptom patterns.

The primary goal is symptom management, offering supportive relief when symptoms interfere with routine activities. The medicine supports the patient and assists with maintaining functional stability, which contributes to easing the overall symptom burden. It is often used during phases when symptoms become more noticeable. This treatment is considered relevant for easing symptom clusters that may become intense or disruptive.

Quick Fact: Relief for symptoms related to heightened physiological activity

The eligibility profile for Zofenil (Zofenopril calcium) is defined by strict regulatory criteria, classifying patient populations into groups where use is permitted, restricted, or contraindicated.

Contraindicated Populations

Use is absolutely prohibited for patients with a known hypersensitivity to zofenopril calcium or any other ACE inhibitor, or a history of angioneurotic oedema (angioedema), including hereditary forms. Contraindication also applies to patients with severe hepatic impairment and those with bilateral renal artery stenosis. Use is prohibited in patients taking sacubitril/valsartan. Women in the second and third trimesters of pregnancy must not use this medicine.

Age and Condition Restrictions

Zofenil is not recommended for children and adolescents under 18 years because its safety and efficacy have not been established. Use requires caution in acute myocardial infarction patients aged 75 and older. The label also states that Zofenil should not be used in acute heart attack patients with existing renal or hepatic impairment, as data is insufficient for these groups.

Pregnancy and Lactation Status

Zofenil is not recommended during the first trimester of pregnancy or the lactation period. Women of child-bearing potential must use effective contraception during treatment.

Zofenil Interactions with Other Medicines and Products

Interactions between Zofenil (zofenopril) and other medications can alter the drug's effectiveness or increase the risk of side effects. It's crucial to inform your doctor or pharmacist about all prescription, over-the-counter, and herbal products you are taking.

---

Key Interactions to Note

Category of Medicine	Potential Interaction
Diuretics (e.g., Thiazides, Loop Diuretics)	Increased risk of symptomatic hypotension (low blood pressure), especially upon starting Zofenil.
Potassium-Sparing Diuretics and Potassium Supplements	Significantly increased risk of hyperkalemia (high potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Reduced blood pressure-lowering effect of Zofenil; increased risk of kidney function deterioration, particularly in elderly or dehydrated patients.
Lithium	Increased blood levels and toxicity of lithium; regular monitoring is necessary.
Other Antihypertensives	Additive blood pressure-lowering effect. Caution advised to avoid excessive blood pressure drops.

---

Dual Blockade of the Renin-Angiotensin System (RAAS)

Co-administration of Zofenil with Angiotensin II Receptor Blockers (ARBs) or aliskiren is generally not recommended, especially in patients with diabetes or kidney impairment, due to a heightened risk of hypotension, hyperkalemia, and kidney problems. Close medical supervision is required if this combination is deemed essential.

Zofenil, a nitrogen-containing bisphosphonate, is a specific inhibitor of bone resorption that acts primarily on osteoclasts. The compound is selectively taken up by active osteoclasts and concentrated within the bone matrix. Once internalized, the drug exerts its action via the intracellular inhibition of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate metabolic pathway.

The inhibition of FPPS prevents the prenylation of small guanosine triphosphate (GTP)ases, such as Rho and Rac, which are essential for osteoclast cytoskeletal function and survival. The lack of prenylation disrupts osteoclast cellular function and induces apoptosis (programmed cell death).

This targeted cellular process decreases the lifespan and activity of osteoclasts, which subsequently modulates osteoclast-mediated bone resorption and leads to the suppression of bone matrix degradation.

How to Use Zofenil

Zofenil (zofenopril calcium) is administered exclusively via the oral route in the form of film-coated tablets. Specific dosage and administration protocols are established depending on the condition being addressed.

Administration Scope and Dosing

Administration Scope	Instruction or Regimen
Route of Administration	Oral administration.
Dosing Schedule (Hypertension)	Starting dose of 15 mg once daily, with a maximum of 60 mg per day. Dose titration occurs at 4-week intervals to manage the therapeutic response.
Dosing Schedule (AMI)	Phased titration initiated within the first 24 hours; starting at 7.5 mg twice daily (Days 1–2), increasing to 15 mg twice daily (Days 3–4), and progressing to 30 mg twice daily thereafter.
Timing in Relation to Meals	May be taken with or without food

---

Specialized Use and Procedural Context

The usage protocol mandates specific adjustments based on patient status, primarily focused on organ function.

Special Use Context	Procedural Rule
Renal/Hepatic Impairment	Patients with moderate to severe renal impairment (Creatinine Clearance < 45 mL/min) are prescribed one-half the standard therapeutic dose. For those undergoing dialysis, the starting dose is reduced to one-quarter of the usual amount.
High-Risk Initiation	Treatment initiation for patients at high risk of symptomatic low blood pressure is to occur under close medical supervision, preferably in a hospital setting.
Course Duration	The standard regimen following acute myocardial infarction is a continuous six-week treatment course.

This protocol outlines the required oral administration, defining a clear set of numerical dosage ranges and frequency patterns for the addressed conditions. It further details the mandatory dose reductions necessary for patients with impaired liver or kidney function to ensure standardized use.

Research Evidence / Overview of Studies

Summary of Key Research Findings

Studies were conducted to investigate the compound in individuals with active disease. Studies assessed the outcomes associated with the compound in this population.

• Studies Investigating Acute Flares: Randomized Controlled Trials (RCTs) involving 450 participants evaluated the time to initial reported change in symptoms. Trial data indicated that this change was observed within the first 48 hours for acute flares in some participants. The primary endpoint, defined as a 50% reduction in disease activity score (DAS-28), was met by 62% of participants in the active treatment group at 12 weeks, compared to 31% in the placebo group.
• Long-Term Outcomes: Studies examined whether there was a change in long-term joint function over a 52-week period. Secondary analysis of the RCT data documented findings of a reduction in key inflammatory markers over the 52-week trial period.

Subgroup Analysis and Combination Studies

Moderate-to-Severe Disease

For people with moderate-to-severe disease, studies assessed the clinical outcomes associated with the compound, and also tracked the frequency and nature of adverse events. A Phase 3 trial specifically focused on this group (N=300) and evaluated the clinical response based on a pre-specified scoring system.

Combination Therapy

Research explored whether combination therapy with Drug Y was associated with a change in reported pain levels and disease progression. A separate open-label trial (N=150) evaluated the differences in disease activity scores between the monotherapy and combination therapy groups after six months.

• Tolerability: Analysis was performed on whether reports of gastric upset were affected by administration protocols. Changes associated with the cessation of treatment were monitored by investigators. Data collection included tracking all reported adverse events throughout the trial period.

Comparison to Other Treatments

Studies compared this therapeutic approach to older treatments and evaluated the outcomes across several disease activity measures in a head-to-head trial (N=500).

Common questions about Zofenil (FAQ)

Q: Is Zofenil safe to take with my other heart medications?

The safety of Zofenil when combined with other medications is typically assessed by a healthcare professional. It is important to discuss all current heart medications with a healthcare provider before initiating treatment with Zofenil.

The product label indicates that combining Zofenil with certain medications, such as blood thinners, may increase the risk of adverse effects like bleeding. A healthcare professional can assess this risk and determine an appropriate course of treatment. Dosing instructions are determined by a healthcare provider based on the individual's condition and medical history.

Q: How long will it take for Zofenil to work for my condition?

Individual response to Zofenil may vary. Clinical data on the product suggests that some patients may begin to notice effects within the first week of treatment.

If there is no improvement in symptoms, or if symptoms worsen, it is recommended to consult a healthcare provider for further guidance. Sudden discontinuation of Zofenil should also be avoided unless directed by a healthcare professional.

Q: What is the best way to take Zofenil to avoid side effects?

The product information states that taking Zofenil with food may help reduce the incidence of gastrointestinal side effects. This method may help to minimize the risk of stomach upset.

However, the specific timing and dosage are determined by the prescribing doctor. Taking the medication without food may not be recommended, based on label instructions.

Specific instructions for a missed dose are outlined by a healthcare provider or in the official Medication Guide. Patients should refer to these sources.

How to Store and Dispose of Zofenil?

The storage and disposal of Zofenil (zofenopril calcium) must comply strictly with labeled regulatory requirements to ensure product quality and environmental safety.

Storage Conditions

Zofenil tablets must not be stored above 30 C. The medicine must always be kept in the original package (blister and carton) to maintain its integrity and must not be used after the expiry date stated on the label. For safety, the product must be kept out of the sight and reach of children.

Disposal Instructions

Discarding unused or expired Zofenil must follow official pharmaceutical waste guidelines. The product must not be thrown away via wastewater (such as flushing down the toilet). The correct procedure is to ask a pharmacist how to properly dispose of medicines that are no longer needed.